PRVA vs RCUS: Which Stock Is the Better Buy?
Privia Health Group, Inc. and Arcus Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — PRVA vs RCUS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Privia Health Group, Inc. (PRVA) | Arcus Biosciences, Inc. (RCUS) | |
|---|---|---|
| Market cap | $2.9B | $2.8B |
| Revenue (latest FY) | $2.12B | $247.00M |
| Net income (latest FY) | $22.92M | $-353.00M |
| Revenue growth (5y CAGR) | 21.0% | 25.9% |
| Net margin | 1.1% | -142.9% |
| Return on equity | 3.1% | -55.9% |
| P/E ratio | 134.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 1 |
| Positive free cash flow | — | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full PRVA vs RCUS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open PRVA's full financials → Open RCUS's full financials →More comparisons
Frequently asked questions
Which is bigger, PRVA or RCUS?
Privia Health Group, Inc. is larger by market capitalization — $2.9B versus $2.8B.
Which grows faster, PRVA or RCUS?
Over the last five fiscal years, Arcus Biosciences, Inc. grew revenue faster — 25.9%/yr versus 21.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
PRVA fundamentals → · RCUS fundamentals → · All 1,500+ companies → · Free screener →